Slide 1: Conquer Cancer through AI
Conquer Cancer through Al © Lunit
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Lunit Inc. solely for information purposes. The information contained in this presentation has not been independently verified. representation No or warranty express or implied is made as to, and no reliance should be placed on, the fairness, accurac
Slide 3: About Lunit
Conquer Cancer through AI HQ Seoul l New York l Amsterdam About Lunit Since 2013 l 1 Generation Medical AI Company l Listed in KOSDAQ since 2022 st Global Investors Global Partners Backed by leading global investors Established partnerships with industry giants · Raised $122M while unlisted Chosen b
Slide 4: Core Competence #1
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Company Overview Core Competence #1 Best-in-Class A.I. Global Recognition Medical Expertise Global leader in AI technology International spotlight Industry leading clinical studies • Top-tier proprietary AI technology • The only Korean company spot
Slide 5: Conquer Cancer through AI
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Company Overview Conquer Cancer through AI Increase cancer survival through AI -powered cancer diagnosis and treatment 1 Cancer diagnosis Chest X-Ray Mammography support solutions 50 % 50% more patients can Chest CT 3D Mammo Flagship (DBT) be scree
Slide 6: Investor Relations
2026 INVESTOR RELATIONS 2021 INVESTOR RELATIONS 6
Slide 7: Product Roadmap: Beyond cancer risk prediction to autonomous AI
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit INSIGHT Roadmap Product Roadmap Beyond cancer risk prediction to autonomous AI Current Risk Assessment Foundation Model Autonomous AI AI-CAD AI-based Risk Prediction AI Customization Autonomous AI in Cancer Screening ▪ Final clinical decision
Slide 8: Higher Reading Accuracy
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit INSIGHT Value Higher Reading Accuracy Better performance than specialists, proven in major studies Evidence Performance Extensively Clinically proven to show excellence in medical image analysis validated through studies Lunit INSIGHT CXR 390
Slide 9: Real World Evidence
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit INSIGHT Value Real World Evidence Building solid evidence through prospective studies Study Method Lunit INSIGHT CXR What is prospective study? Flagship prospective CXR study Study Detection rate of Detection rate of Outcome actionable lung m
Slide 10: Current Commercialization Status
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit INSIGHT Business Current Commercialization Status Usage Partner Testimonials First AI company collaboration for our x-ray business — General Manager K Number of paying sites worldwide 1 “This is actually out first AI company collaboration for
Slide 11: Key Success Factor: Proven to Be Best-in-Class
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit INSIGHT Superior Performance Key Success Factor: Proven to Be Best-in-Class Accuracy Research Partnership Superior Performance Robust Research (SCIE Journals2) Larger Market Access # of Agfa Modality Company (Country) GMM IMS Journals GE Giot
Slide 12: Next Step: Becoming global standard of care
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit INSIGHT Strategy Next Step Becoming global standard of care by B2G expansion and successful reimbursement Active Reimbursement in Japan/Korea, B to G National Cancer Screening Programs Reimbursement Expanding into Other Markets Direct Sales E
Slide 13: Lunit International
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit x Lunit International Lunit Acquires Lunit Internatioal (former “Volpara ”) (May, 2024) Lunit International Future Direction Breast Products Density Reinforce Lung cancer screening Breast Risk Assessment Reinforce XX cancer screening 3,600+ Q
Slide 14: Strong Revenue Growth Driven by Lunit x Lunit International Synergy
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit X Lunit International Strong Revenue Growth Driven by Lunit x Lunit International Synergy Accelerated and Sustained Revenue Growth in Cancer Diagnostics Expected from Lunit x Lunit International Synergy Revenue Trend in Cancer Screening Overs
Slide 15: Direct to Patient Business Model: SecondRead AI
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit x Lunit International Direct to Patient Business Model SecondRead AI Gaining Strong Traction in US Market Traditional Business Model Image Interpretation Lunit INSIGHT DBT $ Patient Provider New Business Model Provider offers SecondReadAI TM
Slide 16: Lunit INSIGHT Risk Assessment Product
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit Cancer Screening Lunit INSIGHT Risk Assessment Product Establishing a new standard for early breast cancer detection and personalized preventive care Before : Risk Assessment Solutions After : Integrated Risk Prediction Solutions Product Deve
Slide 17: Foundation Model
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit Cancer Screening Foundation Model Current: Unified AI Model Overcoming Limitations Through AI Customization ▪ Single AI model for all customer ▪ Maintain high AI accuracy for each customer Periodic Updates of the AI Core Model ▪ AI accuracy v
Slide 18: Data-AI Flywheel Ecosystem
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit Cancer Screening Customization AI for Autonomous AI Requires Platform Approach of Data-AI Flywheel Ecosystem Radiology Images Report Biopsy result EMR Risk Data-AI Flywheel Ecosystem Radiology Imaging Screening Center Hospital Cancer Center C
Slide 19: Our Future is Autonomous AI
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit Cancer Screening Our Future is Autonomous AI Path to Autonomous AI: Customization of AI Model for Each Customer Limitation of current AI applications AI customization using data provided from each site : Single AI model for all customer Data
Slide 20: IO uIHC
2026 INVESTOR RELATIONS IO uIHC 20
Slide 21: Personalized Approach Is Key to Cancer Treatment
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit SCOPE Development Personalized Approach Is Key to Cancer Treatment High Complexity in Cancer KEY: Personalized Treatment by Biomarkers Even cancers in the same organ have Traditional: One general treatment for all cancer patients different bi
Slide 22: Lunit SCOPE: AI-powered Biomarkers for Major Cancer Drugs
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit SCOPE Development Lunit SCOPE: AI-powered Biomarkers for Major Cancer Drugs Cancer Treatment Landscape 20% Others 40% Targeted Therapy Immunotherapy 40% Immune Checkpoint Inhibitors Targeted Small Molecules Global Revenue Chemotherapy Bispeci
Slide 23: Lunit SCOPE: AI-powered Biomarkers for Major Cancer Drugs
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit SCOPE Overview Lunit SCOPE: AI-powered Biomarkers for Major Cancer Drugs Purpose Biomarkers for IO therapeutics Biomarkers for ADCs therapeutics Screening for multiple biomarkers Identification of predictive tissue/cell features Quantificatio
Slide 24: Proven to Be Effective in Pharma Clinical Trials
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit SCOPE & Pharma Proven to Be Effective in Pharma Clinical Trials Currently discussing research agreement/ +20 Global Big Pharma collaboration with leading global pharmas Monotherapy : 3x more responsive when using Lunit SCOPE IO Combotherapy :
Slide 25: Key Clinical Studies for Lunit SCOPE
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit SCOPE Value Key Clinical Studies for Lunit SCOPE High Prediction of Response to uIHC based AI Quantification Prediction of Various Lung Cancer Immunotherapy in Lung Cancer for Various Antibodies Protein Expression Analysis Driver Mutations by
Slide 26: Business Model
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit SCOPE BM Business Model Paired with pharma’s drug,to generatehigh sales by active testing before treatment Pay for Drug $$ Insurance Company Drug Development Process STEP 1 STEP 2 STEP 3 Hospital Patient SCOPE Test If Positive Prescription
Slide 27: Commercialization Roadmap From Pharma Research to CDx
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit SCOPE Commercial Strategy Commercialization Roadmap From Pharma Research to Companion Diagnostics (CDx) Step 1: Biopharma Engagement Step 2: Broader Use, RUOService Step 3: As a CTA Regulatory Approval as CDx CDx Sales for Clinical Use Pilot
Slide 28: Strong Traction with Major Industry Vendors
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit SCOPE Channels Strong Traction with Major Industry Vendors for Future Distribution Scalability Pathology Labs Among Top5 Labs, Top 5 Anatomic Pathology Labs Based on Revenue 1 Labcorp We are engaged with -as well as other key CROs 2 2 Quest 3
Slide 29: Next Steps
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Lunit Oncology Next Steps Cover All Types of Drugs Multi -omic Biomarkers Drug Discovery & Development Lunit SCOPE will be able to cover all Lunit SCOPE will deliver optimal cancer Lunit SCOPE biomarkers shall be applied to types of oncology drugs
Slide 30: Vision
Vision Conquer Cancer through AI -powered Precision Medicine Having strong faith that a data -driven approach is the future, Lunit will be the center of cancer care Globally become the new standard of care Personalized Screening / Diagnosis Personalized Treatment Precision Precision Precision Precis
Slide 31: Thank You
THANK YOU @Lunit
Slide 32: Consolidated Financial Statements
Company Overview Lunit INSIGHT Lunit SCOPE Appendix Appendix Consolidated Financial Statements Statement of Financial Position Unit:KRW million Income Statement Unit:KRW million 1H 1H 2025 2024 2023 2025 2024 2023 2026 2026 Current Asset 217,163 55,620 111,882 230,418 Operating Income 45,766 83,129